Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT06639360

Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke

Led by Xijing Hospital · Updated on 2025-12-04

60

Participants Needed

1

Research Sites

73 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.

CONDITIONS

Official Title

Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old
  • Imaging shows infarction caused by occlusion of the terminal internal carotid artery or M1/M2 segment of the middle cerebral artery
  • Head CT within 24 hours of onset shows ASPECT score of 6 or higher and meets thrombectomy criteria
  • Pre-stroke modified Rankin Scale score of 1 or less
  • NIH Stroke Scale score between 6 and 25 before thrombectomy
  • Successful vascular recanalization with mTICI score greater than 2b/3
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Contraindications to transcranial magnetic stimulation such as metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants
  • Epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases
  • Severe functional impairment of heart, liver, or kidneys
  • Head CT/MRI shows midline shift, significant mass effect, or planned surgical intervention
  • Acute cerebral infarction on both sides of the brain
  • Pregnancy or breastfeeding
  • Severe mental disorders or dementia preventing cooperation with follow-up
  • Other severe diseases with expected survival less than 90 days
  • Participation in other interventional clinical studies within 30 days before this study or after condition onset
  • Inability to cooperate with informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Xijing Hospital

Xi'an, Shaanxi, China, 710032

Actively Recruiting

Loading map...

Research Team

J

Jingjing Zhao, Dr.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here